Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Regadenoson - Astellas Pharma/Rapidscan Pharma Solutions/Gilead Sciences

Drug Profile

Regadenoson - Astellas Pharma/Rapidscan Pharma Solutions/Gilead Sciences

Alternative Names: CVT 3146; Lexiscan; Rapiscan

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CV Therapeutics
  • Developer Astellas Pharma; GE Healthcare; Gilead Sciences; National Jewish Health; Rapidscan Pharma Solutions
  • Class Imaging agents; Purines; Pyrazoles; Small molecules; Vasodilators
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary disorders
  • No development reported Pulmonary hypertension

Most Recent Events

  • 30 Dec 2022 The Court of Appeals for the Federal Circuit affirms the decision of the U.S. District Court for the District of Delaware regarding patent infringement related to regadenoson injection by Hospira
  • 20 May 2022 Astellas Pharma confirms unfavorable district court decision in regadenoson patent trial
  • 15 Feb 2022 The EMA approves regadenoson for stress cardiac magnetic resonance imaging for Coronary disorders (Diagnosis) in European Union
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top